Effective suppression of recurrent prostate cancer cell proliferation by interrupting this pathway has necessitated the synthesis of multiple, specific and effective drugs with anti-hormone and/or anti-AR activity including estrogens, LHRH agonists, and more [36]. This evidence concerns the gene GNRH1 and prostate carcinoma.